- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00310141
Computer-Assisted Counseling in Helping African American Smokers Stop Smoking
Treatment of Nicotine Dependence Among African Americans
RATIONALE: Stop-smoking plans using a nicotine patch, in-person counseling, and computer-assisted counseling may help people stop smoking.
PURPOSE: This randomized clinical trial is studying how well computer-assisted counseling helps African American smokers stop smoking.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Develop and evaluate the efficacy of an interactive, culturally sensitive, individualized, palmtop computer-delivered smoking cessation intervention for African American smokers.
- Examine how hypothesized treatment mechanisms mediate the effects of computer-delivered treatment on abstinence.
OUTLINE: This is a randomized study. A subset of 20 participants are assigned to arm II for pilot testing. All other participants are randomized to 1 of 2 intervention arms.
- Arm I (standard care [SC]): Participants receive nicotine patch therapy on days -5 to 31. Participants also receive a Pathways to Freedom self-help guide and undergo 5 in-person counseling sessions based on the Treating Tobacco Use and Dependence Clinical Practice Guideline. The counseling sessions occur at 12 and 5 days prior to the quit smoking date and at 3, 10, and 31 days after the quit smoking date.
- Arm II (computer-delivered treatment [CDT]): Participants receive the same intervention as in arm I. Participants also undergo CDT for 6 weeks comprising 5 modules (quitting strategies; motivation and support; general smoking information; calendars and fun stuff; and daily tips) beginning 12 days prior to the quit smoking date and continuing for 31 days after the quit smoking date.
All participants complete questionnaires at baseline, during the counseling sessions, and then at approximately 6 months after the quit smoking date.
After completion of study intervention, participants are followed at approximately 6 months.
PROJECTED ACCRUAL: A total of 500 participants will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- University of Texas MD Anderson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- African American
- Age 21 to 65 years
- Current Smoker (history of at least 5 cigarettes/day for the last year)
- Motivated to quit within the next 14 days
- Participants must provide a viable home address and functioning home telephone number
- Can speak, read, write in English at a sixth-grade literacy level
- Provide viable collateral contact information
- Register "8" or more on a carbon monoxide breath test
Exclusion Criteria:
- Contraindication for nicotine patch use
- Active substance dependence (exclusive of nicotine dependence)
- Regular use of tobacco products other than cigarettes (cigars, pipes, smokeless)
- Use of bupropion or nicotine products other than nicotine patches supplied by the study
- Pregnancy or lactation
- Any active illness that precludes full participation in the study protocol
- Another household member enrolled in the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Standard Care Group
Written self-help materials, counseling, and 6-week nicotine patch supply
|
In-person counseling (5 sessions)
6-week supply of the nicotine patch
|
|
Aktiver Komparator: Computer Treatment Group (CDT)
Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
|
In-person counseling (5 sessions)
6-week supply of the nicotine patch
6 weeks of computer delivered treatment for quitting smoking
|
|
Experimental: CDT Pilot
Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
|
In-person counseling (5 sessions)
6-week supply of the nicotine patch
6 weeks of computer delivered treatment for quitting smoking
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Smoking status by SRNT Smoking Status Questionnaire 6 months after treatment
Zeitfenster: 6 months after treatment
|
Abstinence measures are collected at four post cessation follow-up visits.
Point prevalence serving as the primary outcome measure.
Primary outcome analyses will use data from all of the follow-up visits.
SRNT Abstinence Status Questionnaire (Hughes et al., 2003) surveys the tobacco use by the participant and persons within the participant's household and social surroundings.
The questionnaire also collects data on the use of other tobacco products and nicotine replacement medications.
The pre- and post-quit versions of this questionnaire have been adapted to specific timepoints corresponding to participant visits.
|
6 months after treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Contemplating smoking by Contemplation Ladder 6 months after treatment
Zeitfenster: 6 months after treatment
|
The Contemplation Ladder (Biener & Abrams, 1991) assesses readiness to quit smoking and ranges from 0-10 with 0 being "no thought of quitting" and 10 being "taking action to quit" (e.g., cutting down, enrolling in a program).
|
6 months after treatment
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienstuhl: David W. Wetter, PhD, MS, M.D. Anderson Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Lungentumoren
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Cholinerge Wirkstoffe
- Ganglionäre Stimulanzien
- Nikotin-Agonisten
- Cholinerge Agonisten
- Nikotin
Andere Studien-ID-Nummern
- ID01-234
- P30CA016672 (US NIH Stipendium/Vertrag)
- R01CA094826 (US NIH Stipendium/Vertrag)
- MDA-ID-01234 (Andere Kennung: UT MD Anderson Cancer Center)
- CDR0000466339 (Registrierungskennung: NCI PDQ)
- NCI-2012-01637 (Registrierungskennung: NCI CTRP)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .